The ASCO Special Article by Basch et al, entitled, “Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update” (J Clin Oncol 29:4189–4198, 2011), contained errors.
In Table 3, “Antiemetic Dosing by Chemotherapy Risk Category,” in the third row under the high emetic risk category (“Corticosteroid”), dexamethasone dosing information for patients treated with fosaprepitant was inadvertently omitted. The dexamethasone dosing information given in the previous version of the table applied only to patients treated with aprepitant. The corrected rows are reproduced below.
| Risk Category | Dosing on Day of Chemotherapy | Dosing on Subsequent Days |
|---|---|---|
| Corticosteroid if aprepitant is used† | ||
| Dexamethasone | 12 mg oral or IV | 8 mg oral or IV; days 2 and 3 or days 2-4 |
| Corticosteroid if fosaprepitant is used† | ||
| Dexamethasone | 12 mg oral or IV 8 mg oral or IV day 2; 8 mg oral or IV twice per day on days 3 and 4 |
In addition, the second sentence of the footnote associated with this information (†) was given as “If patients do not receive aprepitant, the dexamethasone dose should be adjusted to 20 mg on day 1 and 16 mg on days 2 to 4,” whereas it should have read, “If patients do not receive an NK1 antagonist, the dexamethasone dose should be adjusted to 20 mg on day 1 and 16 mg on days 2 to 4.”
The online version has been corrected in departure from the print. The authors apologize for the mistake.